The diagnostic test kit company is among several institutes to receive grant money from UK Research & Innovation, a government authority funded by the Department for Science, Innovation & Technology.
A total of EUR5 million has been set aside for malaria intervention in the government’s Horizon Europe Guarantee scheme. The two-year project starts in February.
Abingdon is tasked with developing rapid point-of-care tests to detect plasmodium vivax, a malaria-causing bacterium. The test should replicate laboratory-based methods, but must “translate from small-to-medium enterprise prototype to African-based industrial design”.
RECOMMENDED READING:
The goal is to meet the World Health Organisation’s preferred traits for in-field testing. Once complete, Abingdon will transfer the test to diaTROPIX, a Senegalese firm based at Institut Pasteur Dakar, who will produce more tests locally.
The firm, whose hq is at the Sand Hutton biotech campus, promised to support diaTROPIX in delivering tests “to African communities, particularly those in sub-Saharan Africa”.
Abingdon Chief Executive Chris Yates said: “We are delighted to have won this grant award as part of a world-leading group of institutions. We are excited to add Abingdon Health’s rapid diagnostic test development and manufacturing scale-up expertise to that of our distinguished group of partners.”
Other bodies to receive funding include Institut Pasteur, Armauer Hansen Research Institute and the London School of Hygiene & Tropical Medicine.
